Why NovaBridge Biosciences’s (NBP) Stock Is Up 6.17%
As of Tuesday, October 27, NovaBridge Biosciences’s NBP share price has surged by 6.17%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why NovaBridge Biosciences’s (NBP) Stock Is Down 5.47%
As of Monday, October 26, NovaBridge Biosciences’s NBP share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NovaBridge Biosciences’s (NBP) Stock Is Down 8.39%
As of Monday, October 26, NovaBridge Biosciences’s NBP share price has dipped by 8.39%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NovaBridge Biosciences’s (NBP) Stock Is Down 9.85%
As of Monday, October 26, NovaBridge Biosciences’s NBP share price has dipped by 9.85%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why NovaBridge Biosciences’s (NBP) Stock Is Down 9.49%
As of Monday, October 26, NovaBridge Biosciences’s NBP share price has dipped by 9.49%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | NBP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $141.5 | $241.2 | 25% |
|
| Shares Out (Mil) | 115.7 | 53.4 | 65% |
|
| Institutional Ownership | 68.3% | 92.9% | 42% |
|
| Float (Mil) | 64.4 | 41.2 | 52% |
|
| Beta | 1.48 | 0.96 | 82% |
|
| Avg Daily Volume (000s) | 517 | 486 | 59% |
|
| Price Change (52-week) |
(73.7%) | 48.4% | 11% |
|
| Growth | NBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (26.4%) | (10.1%) | 16% |
|
| EPS (5yr) | (23.5%) | 15.8% | 11 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (52.4%) | (15.7%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | ($0.910) | ($0.630) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | 1 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | na | ($0.940) | ($1.060) | |
| Year/Year Chg | na | (1.3%) | (44.7%) | |
| Financials | NBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($118) | ($44) | 10% |
|
| EPS (TTM) | ($1.042) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($46) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $25 | $3 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $27 | $177 | 13% |
|
| Valuation | NBP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.71 | 2.25 | 15% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NBP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (53.6%) | (47.3%) | 11% |
|
| ROE | (59.1%) | (53.3%) | 14% |
|
| Liabilities to Assets | 13.1% | 29.7% | 8% |
|
| F-Score | 1 | 2 | 1% |
|
NovaBridge Biosciences did not pass any screens on 10/29/2026.
